scholarly journals Health-related quality of life after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: Results of the phase III OVHIPEC study

2017 ◽  
Vol 28 ◽  
pp. v627
Author(s):  
S. Koole ◽  
W. van Driel ◽  
J. Kieffer ◽  
K. Sikorska ◽  
J. Schagen van Leeuwen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Phase Iii ◽  
Stage Iii ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group

2009 ◽  
Vol 27 (18) ◽  
pp. 2916-2923 ◽  
Author(s):  
Andrew Bottomley ◽  
Corneel Coens ◽  
Stefan Suciu ◽  
Mario Santinami ◽  
Willem Kruit ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Adjuvant Therapy ◽  
Phase Iii ◽  
Stage Iii ◽  
Health Related Quality ◽  
European Organisation ◽  
Related Quality ◽  
Health Related ◽  
Stage Iii Melanoma

PurposeInterferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL). Our trial examined the HRQOL effects of adjuvant pegylated IFN-α-2b (PEG-IFN-α-2b) versus observation in patients with stage III melanoma.MethodsA total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or PEG-IFN-α-2b (n = 627): induction 6 μg/kg/wk for 8 weeks then maintenance 3 μg/kg/wk for an intended total duration of 5 years. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 was used to assess HRQOL.ResultsAt 3.8 years of median follow-up, for the primary end point, recurrence-free survival (RFS), risk was reduced by 18% (hazard rate = 0.82; P = .01) in the PEG-IFN-α-2b arm compared with observation. Significant and clinically meaningful differences occurred with the PEG-IFN-α-2b treatment arm compared with the observation group, showing decreased global HRQOL at month 3 (−11.6 points; 99% CI, −8.2 to −15.0) and year 2 (−10.5 points; 99% CI, −6.6 to −14.4). Many of the other scales showed statistically significant differences between scores when comparing the two arms. From a clinical point of view, important differences were found for five scales: two functioning scales (social and role functioning) and three symptom scales (appetite loss, fatigue, and dyspnea), with the PEG-IFN-α-2b arm being most impaired.ConclusionPEG-IFN-α-2b leads to a significant and sustained improvement in RFS. There is an expected negative effect on global HRQOL and selected symptoms when patients undergo PEG-IFN-α-2b treatment.

Sign in / Sign up

Export Citation Format

Share Document